Higher Myocardial Infarction Care Payments Improve Mortality

Share this content:
Higher Myocardial Infarction Care Payments Improve Mortality
Higher Myocardial Infarction Care Payments Improve Mortality

THURSDAY, March 22, 2018 (HealthDay News) -- Higher 30-day payments for acute myocardial infarction (AMI) care for both inpatient care and in multiple settings after discharge are associated with lower 30-day mortality among Medicare beneficiaries, according to a study published online March 12 in Circulation: Cardiovascular Quality and Outcomes.

Rishi K. Wadhera, M.D., from Brigham and Women's Hospital in Boston, and colleagues used Medicare claims data to identify 642,105 Medicare fee-for-service beneficiaries at least 65 years old who were hospitalized at an acute-care hospital for AMI between July 1, 2011, and June 30, 2014. The association between hospital-level 30-day payments for an episode of AMI care and patient 30-day mortality was assessed.

The researchers found that overall mean 30-day episode payments per beneficiary were $22,128, and the observed 30-day mortality rate was 12.9 percent. After adjusting for patient characteristics and comorbidities, higher 30-day payments were associated with lower 30-day mortality (P < 0.001). Additional adjustment for hospital characteristics, coronary revascularization rates, and discharge disposition did not significantly attenuate the relationship (P < 0.001).

"Higher hospital-level 30-day payments -- both inpatient and in multiple settings after discharge -- for AMI care were associated with lower 30-day mortality among beneficiaries," the authors write. "This may have implications for payment programs that incent reduction in payments without considering value."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

Doctors Remove Contact Lens Embedded in Eyelid for Years

Doctors Remove Contact Lens Embedded in Eyelid for ...

Lens was encapsulated within the upper eyelid soft tissue since childhood eye trauma

CDC: Brucellosis in Dogs Remains a Public Health Risk

CDC: Brucellosis in Dogs Remains a Public Health ...

Infection is under-recognized, may remain a threat without stronger intervention measures

is free, fast, and customized just for you!




Already a member?

Sign In Now »